# Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

> **NCT02388906** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 906 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **OTHER:** Placebo matching Ipilimumab
- **OTHER:** Placebo matching Nivolumab

## Key facts

- **NCT ID:** NCT02388906
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-16
- **Primary completion:** 2018-11-26
- **Final completion:** 2024-10-16
- **Target enrollment:** 906 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388906, "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02388906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*